Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE versus METHYLERGONOVINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE versus METHYLERGONOVINE MALEATE.
HYDERGINE vs METHYLERGONOVINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
1-2 mg orally three times daily.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Category C
Category D/X
Ergot Alkaloid
Ergot Alkaloid